Glargine once versus twice daily

Comparative efficacy of once daily versus twice daily insulin glargine in children with type 1 diabetes - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059275

Enrollment

Registered

2023-10-30

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E109- Type 1 diabetes mellitus without complications

Interventions

Intervention1: glargine will be administered twice daily: same units of glargine which the patient was previously using (dose will depend on glycemic control of patient before starting study) will be

Eligibility

Inclusion criteria

Inclusion criteria: HbA1c >7.5 on insulin for atleast 1 year

Exclusion criteria

Exclusion criteria: past history of recurrent severe hypoglycemia

Design outcomes

Primary

Measure	Time frame
mean difference in HbA1c levelsTimepoint: 3 months	—

Secondary

Measure	Time frame
hypoglycemic episodesTimepoint: 3 months	—

Countries

India

Contacts

Public ContactSurbhi Bharti

government medical college and hospital chandigarh

vishal_guglani@yahoo.com7876161007

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026